致：香港交易及結算所有限公司 公司名稱: 美瑞健康國際產業集團有限公司 呈交日期: 2025年12月1日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02327 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 ...

Group 1 - The core point of the article highlights the recent stock transfer of Meirui Health International (02327) from CITIC Securities to Minyin Securities, with a market value of HKD 68.7648 million, representing 6.11% of the total shares [1] - Meirui Health International reported its interim results for the six months ending June 30, 2025, showing a revenue of HKD 17.453 million, a year-on-year decrease of 41.89% [1] - The company recorded a profit attributable to shareholders of HKD 15.157 million, reflecting a year-on-year increase of 79.05%, with earnings per share at HKD 0.0037 [1]

Group 1 - The core point of the article highlights the recent stock transfer of Meirui Health International (02327) from CITIC Securities to Minyin Securities, with a market value of HKD 68.7648 million, representing 6.11% of the total shares [1] - Meirui Health International reported a revenue of HKD 17.453 million for the six months ending June 30, 2025, which is a year-on-year decrease of 41.89% [1] - The profit attributable to the company's owners was HKD 15.157 million, showing a significant year-on-year increase of 79.05%, with earnings per share at HKD 0.0037 [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 美瑞健康國際產業集團有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02327 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | 10,000,000,000 | | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 美瑞健康國際產業集團有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02327 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | 10,000,000,000 | | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | ...

Dear Sir/Madam, Notification of Publication of Interim Report 2025 (the "Current Corporate Communication") Meilleure Health International Industry Group Limited (the "Company") hereby notifies you that the Current Corporate Communication, in both English and Chinese versions, is available on the Company's website at www.meilleure.com.cn and the HKExnews' website at www.hkexnews.hk. You may access the Current Corporate Communications by either (i) clicking "Investor Relations" on the home page of the Company ...

MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED 美瑞健康國際產業集團有限公 司 (Incorporated in Bermuda with limited liability) (Stock Code 股份代號：2327) （於百慕達註冊成立之有限公司） NOTIFICATION LETTER 通知信函 22 September 2025 Dear Shareholders Meilleure Health International Industry Group Limited (the "Company") – Notice of Publication of Interim Report 2025 (the "Current Corporate Communication") English and Chinese versions of the Current Corporate Communication are available under the Investor Relations section of the Company's ...

Financial Performance - Revenue for the six months ended June 30, 2025, was approximately HKD 17.5 million, a decrease of about 41.7% from HKD 30.0 million for the same period in 2024[13] - Gross profit for the same period was approximately HKD 14.2 million, down about 7.8% from HKD 15.4 million in 2024, with a gross margin increase from 51.3% to 81.1%[16] - Other income and net gains for the six months ended June 30, 2025, were approximately HKD 22.6 million, a decrease of about 30.7% from HKD 32.6 million in 2024[17] - Profit after tax for the six months ended June 30, 2025, was approximately HKD 15.1 million, an increase of about 84.1% from HKD 8.2 million in 2024[20] - The decline in revenue was primarily due to a decrease in sales of construction materials by approximately HKD 8.7 million and health-related products by approximately HKD 3.5 million[13] - The increase in gross margin was attributed to a lower proportion of revenue from the trading business, which has a lower gross margin compared to other business segments[16] - Interest income rose from approximately HKD 8.9 million in 2024 to approximately HKD 14.8 million in 2025, contributing to the overall financial performance[17] - The group reported a loss of approximately HKD 1.0 million in the trade business for the six months ended June 30, 2025, compared to a profit of approximately HKD 66,000 for the same period in 2024, a decline of about 115.2%[24] Assets and Liabilities - Non-current assets increased to approximately HKD 999.0 million as of June 30, 2025, from HKD 980.4 million as of December 31, 2024, an increase of about HKD 18.6 million[29] - Current assets rose to approximately HKD 750.1 million as of June 30, 2025, from HKD 688.3 million as of December 31, 2024, an increase of about HKD 61.8 million[29] - Total liabilities increased to approximately HKD 530.1 million as of June 30, 2025, from HKD 467.3 million as of December 31, 2024, an increase of about HKD 62.8 million[30] - The group’s net asset value as of June 30, 2025, was approximately HKD 1,218.9 million, compared to HKD 1,201.4 million as of December 31, 2024[27] - As of June 30, 2025, the total outstanding loans receivable amounted to HKD 505,383,000, with the largest borrower, Guangyu Zhaoneng, accounting for 43.3% of the total at HKD 219,160,000[53] Cash Flow - The net cash used in operating activities for the six months ended June 30, 2025, was approximately HKD 13.4 million, compared to a net cash inflow of HKD 109.3 million for the same period in 2024[32][33] - The net cash used in investing activities was approximately HKD 22.1 million, mainly due to short-term interest-bearing loans of approximately HKD 39.1 million issued to independent third parties, partially offset by interest income of approximately HKD 13.0 million[33] - The net cash generated from financing activities was approximately HKD 15.1 million, primarily from new bank loans of approximately HKD 48.3 million, offset by loan repayments of approximately HKD 19.3 million and share buybacks of approximately HKD 8.9 million[34] Shareholder Information - The board has declared an interim dividend of HKD 0.15 per share for the six months ending June 30, 2025, totaling approximately HKD 6,141,000[86] - The interim dividend will be paid on October 31, 2025, to shareholders listed on October 2, 2025[86] - The company repurchased a total of 29,706,000 shares at a total cost of HKD 8,847,264[120] Employee and Management - As of June 30, 2025, the group had a total of 49 employees, an increase from 46 employees as of December 31, 2024[62] - The company is committed to employee training and development to align with strategic goals and customer requirements[63] Market and Industry Trends - The health industry in China is projected to reach a market size of over RMB 16 trillion by 2030, indicating significant growth potential[66] - By the end of 2024, the population aged 60 and above in China is expected to reach 310 million, accounting for 22% of the total population, driving demand in the health sector[67] - The "silver economy" market size has surpassed RMB 9 trillion, reflecting the growing needs of the aging population[67] - The health industry is experiencing rapid growth due to increased consumer demand for preventive medicine and personalized health management[67] Strategic Focus - The company continues to believe in the significant potential of the health industry, focusing on leveraging technology and professional services to enhance health and beauty[45] - The company is focusing on the development of cell therapy and health management businesses, leveraging its extensive experience in skin health management[68] - The company aims to optimize its product offerings by combining skincare products with medical aesthetics, enhancing effectiveness in skin health management[68] Research and Development - The company has made strategic investments in the cell therapy sector, including a strategic stake in a national high-tech enterprise in 2019 and the establishment of a new entity in 2020 focused on cell immunotherapy[71] - The company has been granted multiple patents related to stem cell preparation methods and artificial intelligence monitoring systems, enhancing its technological capabilities[72] - The company is actively involved in clinical collaborations with several medical institutions to accelerate the clinical translation of scientific achievements[72] Corporate Governance - The company has adopted the principles of the Corporate Governance Code and complied with all applicable code provisions[125] - The board of directors confirmed compliance with the standards set out in the Model Code for Securities Transactions by Directors[126] - The audit committee reviewed the group's accounting principles and practices, including the unaudited interim financial information for the six months ended June 30, 2025[127]

Core Insights - The latest shareholder equity disclosures for Mei Rui Health International, Huaxin Cement, and Yingxing Holdings were made on September 15, 2025 [1] Group 1: Mei Rui Health International (02327) - Shunda Investment increased its holdings from 2.322 billion shares to 2.328 billion shares, representing a holding percentage change from 56.71% to 56.86% [2] - Zhongjia U-Home Investment Limited raised its stake from 1.357 billion shares to 1.364 billion shares, with a holding percentage change from 33.16% to 33.31% [2] - Yuan Yakang and Shenzhen Kangchengheng Capital both reduced their holdings from 42.02 million shares to 40.69 million shares, resulting in a holding percentage change from 13.24% to 12.82% [2] - HHLR Advisors, Ltd. decreased its holdings from 8.3232 million shares to 7.7254 million shares, with a holding percentage change from 5.34% to 4.95% [2] Group 2: Huaxin Cement (06655) - Ming Jinhua increased his holdings from 189,300 shares to 209,800 shares, maintaining a holding percentage of 0.03% [2] Group 3: Yingxing Holdings (01440) - Liang Bingde acquired 50,000 shares, marking a new holding with a percentage of 0.01% [2]

Group 1 - The core point of the article highlights the recent stock transfer of Meirui Health International from CITIC Securities Hong Kong to Minyin Securities, with a market value of HKD 106 million, representing 9.41% of the total shares [1] - Meirui Health International reported its interim results for the six months ending June 30, 2025, showing a revenue of HKD 17.453 million, a year-on-year decrease of 41.89% [1] - The profit attributable to the company's owners was HKD 15.157 million, reflecting a year-on-year increase of 79.05%, with earnings per share at HKD 0.37 [1]